Advisors Asset Management Inc. Purchases 1,742 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Advisors Asset Management Inc. lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 130.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,077 shares of the company’s stock after purchasing an additional 1,742 shares during the quarter. Advisors Asset Management Inc.’s holdings in Cellebrite DI were worth $52,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. boosted its stake in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after buying an additional 1,017 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Cellebrite DI during the 2nd quarter worth about $71,000. Pathway Financial Advisers LLC boosted its position in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. nVerses Capital LLC bought a new stake in Cellebrite DI in the second quarter valued at about $103,000. Finally, TD Asset Management Inc acquired a new position in Cellebrite DI in the second quarter worth about $121,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Craig Hallum lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft boosted their price target on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, TD Cowen increased their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Buy” and an average target price of $20.29.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $20.18 on Friday. The firm has a 50 day simple moving average of $18.22 and a 200 day simple moving average of $15.16. Cellebrite DI Ltd. has a fifty-two week low of $7.91 and a fifty-two week high of $21.00. The firm has a market cap of $4.16 billion, a P/E ratio of -13.02, a P/E/G ratio of 2.71 and a beta of 1.50.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.09 earnings per share. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.32 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.